Abstract: Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants.

Abstract: Avian pathogenic bacteria, such as avian pathogenic E. coli (APEC) and Salmonella, cause severe infections in poultry products such as chickens and turkeys leading to food contamination and disease in humans. Previously, antibiotics were used to control bacterial infections and growth, contributing to more multi-drug resistant bacterial strains. The increased restrictions on the use of antibiotics in food-producing animals necessitate the development of new antibiotic alternative therapies. Here, the efficacy of novel antibacterial probiotics and peptides were tested against APEC and Salmonella infections in chickens. The alternative treatment methods disclosed herein are needed to combat these foodborne pathogens in avian animals and to help decrease the use of conventional antibiotics in poultry.

Abstract: Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Abstract: Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Abstract: Disclosed herein are methods of treating a subject with a bacterial infection preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, of a derivative thereof, having the formula of SM1, SM3, SM4 or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, testing the formula of SM1, SM3, SM4, or SM5. The methods are effective against the area of bacterial pathogens in various animals and plants.

Abstract: Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants.

Abstract: Disclosed are anti-avian pathogenic E. coli (APEC) agents as well as methods of using thereof.

Abstract: Compounds and compositions of matter are provided that are small molecule antimicrobials. The compounds are selected from JH-144, TH-04 or TH-08 or combinations thereof. Compositions of matter are provided which in an embodiment may comprise a carrier, and in further embodiments may comprise a pharmaceutically acceptable excipient, film, biofilm or edible film. Methods of use are provided in which the composition may be administered to a subject in need thereof, and in an embodiment where the subject has a bacterial infection. Other embodiments provide the composition may be contacted with surface to eliminate or reduce bacteria.

Abstract: Disclosed herein are methods of treating a subject with a bacterial infection, or preventing a bacterial infection, comprising administering to the subject an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. Also described are methods of inhibiting bacterial growth in a plant comprising contacting the plant with an effective amount of at least one compound, or a derivative thereof, having the formula of SM1, SM3, SM4, or SM5. The methods are effective against an array of bacterial pathogens in various animals and plants.

Abstract: Compounds and compositions of matter are provided that are small molecule antimicrobials. The compounds are selected from JH-144, TH-04 or TH-08 or combinations thereof. Compositions of matter are provided which in an embodiment may comprise a carrier, and in further embodiments may comprise a pharmaceutically acceptable excipient, film, biofilm or edible film. Methods of use are provided in which the composition may be administered to a subject in need thereof, and in an embodiment where the subject has a bacterial infection. Other embodiments provide the composition may be contacted with surface to eliminate or reduce bacteria.

Abstract: The subject matter disclosed herein generally relates to modulators of Clavibacter michiganensis subsp. michiganensis, derivatives thereof, formulations thereof, coated seeds, and methods of using such compounds to treat diseases such as bacterial canker in plants.

Abstract: The subject matter disclosed herein generally relates to modulators of Clavibacter michiganensis subsp. michiganensis, derivatives thereof, formulations thereof, coated seeds, and methods of using such compounds to treat diseases such as bacterial canker in plants.

Abstract: Clavibacter michiganensis subsp. michiganensis (Cmm) is an important Gram-positive-bacterial pathogen that infects tomato plants causing wilting and cankers and leading to severe economic losses in commercial tomato production worldwide. In order to visualize the infection process of Cmm in germinating seeds, bioluminescent Cmm strains were constructed by transforming the lux reporter gene into the bacterium. A vector pXX2 was constructed by inserting a modified promoterless lux-operon to a Cmm transposon mutagenesis vector, pKGT452C?. After electroporation, pXX2 carrying the Cmxr::luxABCDE::Tn1409 cassette resulted in insertion of lux-operon into the Cmm chromosome. The virulent, stable, constitutively bioluminescent strain BL-Cmm17 was selected for further characterization of growth properties and inoculation on tomato seeds. Using this bioluminescent strain, Cmm colonization dynamics of germinating seeds were monitored in real-time using the in vivo imaging system (IVIS).

Abstract: Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms. Functional inactivation of galE, a virB gene or the operon (ORFs 1087-1090) comprising the gene encoding ?-hexosaminidase (BMEI1087) and a lytic murein transglycosylase gene (BMEI1088). A specific example of the attenuated galE mutant which produces a protective immune response is B. melitensis GR024. The specific example of an inactivated ORF1087-1090 operon is B. melitensis GR026; it has an insertion mutation in the promoter region upstream of ORF 1090. Vaccination with live cells of either or both of these mutants results in a T cell response which protects the human or animal against challenge with virulent B. melitensis.

Abstract: Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms. Functional inactivation of galE, a virB gene or the operon (ORFs 1087-1090) comprising the gene encoding ?-hexosaminidase (BMEI1087) and a lytic murein transglycosylase gene (BMEI1088). A specific example of the attenuated galE mutant which produces a protective immune response is B. melitensis GR024. The specific example of an inactivated ORF1087-1090 operon is B. melitensis GR026; it has an insertion mutation in the promoter region upstream of ORF 1090. Vaccination with live cells of either or both of these mutants results in a T cell response which protects the human or animal against challenge with virulent B. melitensis.

Abstract: Certain attenuated mutants of Brucella, especially B. melitensis, B. abortus, B. suis and B. ovis, when administered to a human or animal trigger a protective immune response such that subsequent challenge with virulent Brucella of the same species does not result in disease or results in much less severe symptoms. Functional inactivation of galE, a virB gene or the operon (ORFs 1087-1090) comprising the gene encoding ?-hexosaminidase (BMEI1087) and a lytic murein transglycosylase gene (BMEI1088). A specific example of the attenuated galE mutant which produces a protective immune response is B. melitensis GR024. The specific example of an inactivated ORF1087-1090 operon is B. melitensis GR026; it has an insertion mutation in the promoter region upstream of ORF 1090. Vaccination with live cells of either or both of these mutants results in a T cell response which protects the human or animal against challenge with virulent B. melitensis.

Abstract: A truncated SE fimbria antigen useful as an antigen for immunoassay diagnosis of Salmonella enteritidis (SE) infection or evidence of infection.